Non-Vitamin K Antagonist Oral Anticoagulants in Differentiated Approach to the Use in Cardiological Practice: Literature Review

DOI: https://doi.org/10.30702/ujcvs/23.31(03)/VD041-111126
Keywords: novel oral anticoagulants, rivaroxaban, apixaban, pharmacokinetics, adverse events, antidote, atrial fibrillation, anticoagulants

Abstract

Non-vitamin K antagonist oral anticoagulants (novel oral anticoagulants, NOACs) are important pharmaceuticals for prevention of stroke and systemic embolism in non-valvular atrial fibrillation patients. Vitamin K antagonist warfarin usage is limited due to its pharmacokinetic and pharmacodynamic parameters. In modern conditions, NOACs are widely used. This literature review includes the most interesting clinical studies where anticoagulants were used. Main pharmacological properties of non-vitamin K antagonist oral anticoagulants have been investigated in these clinical studies.

The aim. To answer the question about which anticoagulant is preferable for use in particular clinical situation.

Results. In order to prevent venous thrombosis, conservative and surgical treatment is used. It is the use of anticoagulants during conservative therapy that allows to extend the life expectancy of patients at high risk of thrombosis. Unlike warfarin, the use of NOACs helps to avoid high risk of bleeding. Drugs of this group have short half-life, standard dosage, and predicted pharmacological effect.

Conclusions. New data about comparative efficacy and safety of treatment with NOACs (dabigatran, rivaroxaban, edoxaban, apixaban) in order to prevent thromboembolism in patients with atrial fibrillation are presented. The peculiarities of anticoagulant therapy in elderly patients, patients with coronary artery disease, atrial fibrillation, chronic kidney disease, patients in pre- and postoperative periods are discussed. Prolonged study of drugs of this group will enable doctors to use them without endangering the patients’ lives. NOACs, despite obtained data about their effectiveness and safety, in our opinion, deserve attention and require further study.

References

  1. Connolly SJ, Eikelboom JW, Bosch J, Dagenais G, Dyal L, Lanas F, et al.; COMPASS investigators. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391(10117):205-218. https://doi.org/10.1016/S0140-6736(17)32458-3
  2. Sindet-Pedersen C, Staerk L, Lamberts M, Gerds TA, Berger JS, Nissen Bonde A, et al. Use of oral anticoagulants in combination with antiplatelet(s) in atrial fibrillation. Heart. 2018;104(11):912-920. https://doi.org/10.1136/heartjnl-2017-311976
  3. Lasica R, Asanin M, Djukanovic L, Radovanovic N, Savic L, Polovina M, et al. Dilemmas in the Choice of Adequate Therapeutic Treatment in Patients with Acute Pulmonary Embolism-From Modern Recommendations to Clinical Application. Pharmaceuticals (Basel). 2022 Sep 14;15(9):1146. https://doi.org/10.3390/ph15091146
  4. Giustozzi M, Franco L, Vedovati MC, Becattini C, Agnelli G. Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism. J Thromb Thrombolysis. 2019;48(3):439-453. https://doi.org/10.1007/s11239-019-01878-x
  5. Ageno W, Beyer-Westendorf J, Rubboli A. Once-versus twice-daily direct oral anticoagulants in non-valvular atrial fibrillation. Expert Opin Pharmacother. 2017;18(13):1325-1332. https://doi.org/10.1080/14656566.2017.1361405
  6. van Rein N, Heide-Jørgensen U, Lijfering WM, Dekkers OM, Sørensen HT, Cannegieter SC. Major Bleeding Rates in Atrial Fibrillation Patients on Single, Dual, or Triple Antithrombotic Therapy. Circulation. 2019;139(6):775-786. https://doi.org/10.1161/CIRCULATIONAHA.118.036248
  7. Kumbhani DJ, Cannon CP, Beavers CJ, Bhatt DL, Cuker A, Gluckman TJ, et al. 2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease. J Am Coll Cardiol. 2021;77(5):629-658. https://doi.org/10.1016/j.jacc.2020.09.011
  8. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al.; ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119-177. https://doi.org/10.1093/eurheartj/ehx393
  9. Collet JP, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, et al.; ESC Scientific Document Group. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289-1367. https://doi.org/10.1093/eurheartj/ehaa575
  10. Jung N, Shim YJ. Current Knowledge on Inherited Platelet Function Disorders. Clin Pediatr Hematol Oncol. 2020;27:1-13. https://doi.org/10.15264/cpho.2020.27.1.1
  11. Kitchens CS. Concept of Hypercoagulability: A Review of its Development, Clinical Application, and Recent Progress. Semin Thromb Hemost. 1985;11(3):293-315. https://doi.org/10.1055/s-2007-1004383
  12. Baglin T, Gray E, Greaves M, Hunt BJ, Keeling D, Machin S, et al.; British Committee for Standards in Haematology. Clinical guidelines for testing for heritable thrombophilia. Br J Haematol. 2010;149(2):209-220. https://doi.org/10.1111/j.1365-2141.2009.08022.x
  13. Stevens H, Tran H, Gibbs H. Venous thromboembolism: current management. Aust Prescr. 2019;42(4):123-126. https://doi.org/10.18773/austprescr.2019.039
  14. Hinojar R, Jiménez-Natcher JJ, Fernández-Golfín C, Zamorano JL. New oral anticoagulants: a practical guide for physicians. Eur Heart J Cardiovasc Pharmacother. 2015;1(2):134-145. https://doi.org/10.1093/ehjcvp/pvv002
  15. Burg MR, Ha ACT. Is There a Role for Vitamin K Antagonist in the Management of Atrial Fibrillation in 2023? Curr Cardiol Rep. 2023;25(5):391-399. https://doi.org/10.1007/s11886-023-01863-0
  16. Wiggins BS, Dixon DL, Neyens RR, Page RL 2nd, Gluckman TJ. Select Drug-Drug Interactions With Direct Oral Anticoagulants: JACC Review Topic of the Week. J Am Coll Cardiol. 2020;75(11):1341-1350. https://doi.org/10.1016/j.jacc.2019.12.068
  17. Yeh CH, Hogg K, Weitz JI. Overview of the New Oral Anticoagulants: Opportunities and Challenges. Arterioscler Thromb Vasc Biol. 2015;35(5):1056-1065. https://doi.org/10.1161/ATVBAHA.115.303397
  18. Riva N, Ageno W. Pros and Cons of Vitamin K Antagonists and Non-Vitamin K Antagonist Oral Anticoagulants. Semin Thromb Hemost. 2015;41(2):178-187. https://doi.org/10.1055/s-0035-1544231
  19. Sarich TC, Seltzer JH, Berkowitz SD, Costin’ J, Curnutte JT, Gibson CM, et al. Novel oral anticoagulants and reversal agents: Considerations for clinical development. Am Heart J. 2015;169(6):751-757. https://doi.org/10.1016/j.ahj.2015.03.010
  20. Chen A, Stecker E, A Warden B. Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges. J Am Heart Assoc. 2020 Jul 7;9(13):e017559. https://doi.org/10.1161/JAHA.120.017559
  21. Mueck W, Schwers S, Stampfuss J. Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring. Thromb J. 2013 Jun 28;11(1):10. https://doi.org/10.1186/1477-9560-11-10
  22. Chan N, Sager PT, Lawrence J, Ortel T, Reilly P, Berkowitz S, et al. Is there a role for pharmacokinetic/pharmacodynamic-guided dosing for novel oral anticoagulants? Am Heart J. 2018;199:59-67. https://doi.org/10.1016/j.ahj.2017.10.002
  23. Mekaj YH, Mekaj AY, Duci SB, Miftari EI. New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag. 2015;11:967-977. https://doi.org/10.2147/TCRM.S84210
  24. Saljoughian M. Assessing Novel Oral Anticoagulants. US Pharm. 2018;43(2):13-14.
  25. Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016;149(2):315-352. https://doi.org/10.1016/j.chest.2015.11.026
  26. Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, et al.; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association. Circulation. 2018;137(12):e67-492. https://doi.org/10.1161/CIR.0000000000000558
  27. Finegold JA, Asaria P, Francis DP. Mortality from ischaemic heart disease by country, region, and age: Statistics from World Health Organisation and United Nations. Int J Cardiol. 2013;168(2):934-945. https://doi.org/10.1016/j.ijcard.2012.10.046
  28. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al.; ESC Scientific Document Group. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119-177. https://doi.org/10.1093/eurheartj/ehx393
  29. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al.; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2020;41(3):407-477. https://doi.org/10.1093/eurheartj/ehz425
  30. Khera S, Kolte D, Bhatt DL. Chapter 16. Percutaneous Coronary Intervention. In: Aronow WS, McClung JA, editors. Translational Research in Coronary Artery Disease. Boston: Academic Press; 2016. p. 179-194. https://doi.org/10.1016/B978-0-12-802385-3.00016-4
  31. McDermott KW, Freeman WJ, Elixhauser A. Overview of operating room procedures during inpatient stays in U.S. hospitals, 2014. Statistical Brief #233. In: Healthcare Cost and Utilization Project (HCUP) Statistical Briefs [Internet]. Rockville (MD): Agency for Healthcare Research and Quality; 2017 December [cited 2023 Aug 8]. Available from: https://hcup-us.ahrq.gov/reports/statbriefs/ sb233-Operating-Room-Procedures-United-States-2014.pdf
  32. Merlini PA, Bauer KA, Oltrona L, Ardissino D, Cattaneo M, Belli C, et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation. 1994;90(1):61-68. https://doi.org/10.1161/01.cir.90.1.61
  33. Andreotti F, Testa L, Biondi-Zoccai GG, Crea F. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. Eur Heart J. 2006;27(5):519-526. https://doi.org/10.1093/eurheartj/ehi485
  34. Rothberg MB, Celestin C, Fiore LD, Lawler E, Cook JR. Warfarin plus Aspirin after Myocardial Infarction or the Acute Coronary Syndrome: Meta-Analysis with Estimates of Risk and Benefit. Ann Intern Med. 2005;143(4):241-250. https://doi.org/10.7326/0003-4819-143-4-200508160-00005
  35. Gibson CM, Mega JL, Burton P, Goto S, Verheugt F, Bode C, et al. Rationale and design of the Anti-Xa Therapy to Lower cardiovascular events in Addition to standard therapy in Subjects with Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 51 (ATLAS-ACS 2 TIMI 51) trial: A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome. Am Heart J. 2011;161(5):815-821.e6. https://doi.org/10.1016/j.ahj.2011.01.026
  36. Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, et al.; ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in Patients with a Recent Acute Coronary Syndrome. N Engl J Med. 2012;366(1):9-19. https://doi.org/10.1056/NEJMoa1112277
  37. APPRAISE Steering Committee and Investigators; Alexander JH, Becker RC, Bhatt DL, Cools F, Crea F, Dellborg M, et al. Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation. 2009;119(22):2877-2885. https://doi.org/10.1161/CIRCULATIONAHA.108.832139
  38. Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, et al.; APPRAISE-2 Investigators. Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome. N Engl J Med. 2011;365(8):699-708. https://doi.org/10.1056/NEJMoa1105819
  39. Oldgren J, Budaj A, Granger CB, Khder Y, Roberts J, Siegbahn A, et al.; RE-DEEM Investigators. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double- blind, phase II trial. Eur Heart J. 2011;32(22):2781-2789. https://doi.org/10.1093/eurheartj/ehr113
  40. Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP, et al.; WOEST study investigators. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013;381(9872):1107-1115. https://doi.org/10.1016/S0140-6736(12)62177-1
  41. Lamberts M, Gislason GH, Olesen JB, Kristensen SL, Schjerning Olsen AM, et al. Oral Anticoagulation and Antiplatelets in Atrial Fibrillation Patients After Myocardial Infarction and Coronary Intervention. J Am Coll Cardiol. 2013;62(11):981-989. https://doi.org/10.1016/j.jacc.2013.05.029
  42. Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med. 2016;375(25):2423-2434. https://doi.org/10.1056/NEJMoa1611594
  43. Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, et al.; RE-DUAL PCI Steering Committee and Investigators. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017;377(16):1513-1524. https://doi.org/10.1056/NEJMoa1708454
  44. Late-Breaking Science Abstracts From the American Heart Association’s Scientific Sessions 2017 and Late- Breaking Abstracts in Resuscitation Science From the Resuscitation Science Symposium 2017. Circulation. 2017;136(24):e448-e467. https://doi.org/10.1161/CIR.0000000000000546
  45. Lopes RD, Vora AN, Liaw D, Granger CB, Darius H, Goodman SG, et al. An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial. Am Heart J. 2018;200:17-23. https://doi.org/10.1016/j.ahj.2018.03.001
  46. Zimetbaum P. Atrial Fibrillation. Ann Intern Med. 2017;166(5):ITC33-ITC48. https://doi.org/10.7326/ AITC201703070. Erratum in: Ann Intern Med. 2017 Jun 20;166(12):920.
  47. Vora A, Kapoor A, Nair M, Lokhandwala Y, Narsimhan C, Ravikishore AG, et al. Clinical presentation, management, and outcomes in the Indian Heart Rhythm Society- Atrial Fibrillation (IHRS-AF) registry. Indian Heart J. 2017;69(1):43-47. https://doi.org/10.1016/j.ihj.2016.06.006
  48. Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY. Underuse of Oral Anticoagulants in Atrial Fibrillation: A Systematic Review. Am J Med. 2010;123(7):638-645.e4. https://doi.org/10.1016/j.amjmed.2009.11.025
  49. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955-962. https://doi.org/10.1016/s0140-6736(13)62343-0
  50. Lip GYH, Keshishian A, Li X, Hamilton M, Masseria C, Gupta K, et al. Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients. Stroke. 2018;49(12):2933-2944. https://doi.org/10.1161/STROKEAHA.118.020232
  51. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery; Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: The Task Force For The Management Of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369-2429. https://doi.org/10.1093/eurheartj/ehq278
  52. Lin HJ, Wolf PA, Kelly-Hayes M, Beiser AS, Kase CS, Benjamin EJ, et al. Stroke Severity in Atrial Fibrillation. The Framingham Study. Stroke. 1996;27(10):1760-1764. https://doi.org/10.1161/01.str.27.10.1760
  53. Lowres N, Neubeck L, Redfern J, Freedman SB. Screening to identify unknown atrial fibrillation. A systematic review. Thromb Haemost. 2013;110(2):213-222. https://doi.org/10.1160/TH13-02-0165
  54. Sandhu RK, Conen D, Tedrow UB, Fitzgerald KC, Pradhan AD, Ridker PM, et al. Predisposing Factors Associated With Development of Persistent Compared With Paroxysmal Atrial Fibrillation. J Am Heart Assoc. 2014 May 1;3(3):e000916. https://doi.org/10.1161/JAHA.114.000916
  55. Oldgren J, Healey JS, Ezekowitz M, Commerford P, Avezum A, Pais P, et al; RE-LY Atrial Fibrillation Registry Investigators. Variations in Cause and Management of Atrial Fibrillation in a Prospective Registry of 15,400 Emergency Department Patients in 46 Countries: The RE-LY Atrial Fibrillation Registry. Circulation. 2014;129(15):1568-1576. https://doi.org/10.1161/CIRCULATIONAHA.113.005451
  56. Piccini JP, Stevens SR, Lokhnygina Y, Patel MR, Halperin JL, Singer DE, et al.; ROCKET AF Steering Committee & Investigators. Outcomes After Cardioversion and Atrial Fibrillation Ablation in Patients Treated With Rivaroxaban and Warfarin in the ROCKET AF Trial. J Am Coll Cardiol. 2013;61(19):1998-2006. https://doi.org/10.1016/j.jacc.2013.02.025
  57. January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019;74(1):104-132. https://doi.org/10.1016/j.jacc.2019.01.011
  58. Capranzano P, Miccichè E, D’Urso L, Privitera F, Tamburino C. Personalizing oral anticoagulant treatment in patients with atrial fibrillation. Expert Rev Cardiovasc Ther. 2013;11(8):959-973. https://doi.org/10.1586/14779072.2013.818819
  59. Kundu A, Sardar P, Chatterjee S, Aronow WS, Owan T, Ryan JJ. Minimizing the Risk of Bleeding with NOACs in the Elderly. Drugs Aging. 2016;33(7):491-500. https://doi.org/10.1007/s40266-016-0376-z
  60. Kuhn-Thiel AM, Weiß C, Wehling M; FORTA authors/ expert panel members. Consensus Validation of the FORTA (Fit fOR The Aged) List: A Clinical Tool for Increasing the Appropriateness of Pharmacotherapy in the Elderly. Drugs Aging. 2014;31(2):131-140. https://doi.org/10.1007/s40266-013-0146-0
  61. Pazan F, Collins R, Gil VM, Hanon O, Hardt R, Hoffmeister M, et al. A Structured Literature Review and International Consensus Validation of FORTA Labels of Oral Anticoagulants for Long-Term Treatment of Atrial Fibrillation in Older Patients (OAC-FORTA 2019). Drugs Aging. 2020;37(7):539-548. https://doi.org/10.1007/s40266-020-00771-0
  62. Haas S. New oral Xa and IIa inhibitors: updates on clinical trial results. J Thromb Thrombolysis. 2008;25(1):52-60. https://doi.org/10.1007/s11239-007-0108-7
  63. Verheugt FW, Granger CB. Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs. Lancet. 2015;386(9990):303-310. https://doi.org/10.1016/S0140-6736(15)60245-8
  64. Hohnloser SH, Basic E, Nabauer M. Changes in Oral Anticoagulation Therapy over One Year in 51,000 Atrial Fibrillation Patients at Risk for Stroke: A Practice-Derived Study. Thromb Haemost. 2019;119(6):882-893. https://doi.org/10.1055/s-0039-1683428
  65. Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021;23(10):1612-1676. https://doi.org/10.1093/europace/euab065
  66. Plitt A, Ezekowitz MD, De Caterina R, Nordio F, Peterson N, Giugliano RP; ENGAGE AF-TIMI 48 Investigators. Cardioversion of Atrial Fibrillation in ENGAGE AF-TIMI 48. Clin Cardiol. 2016;39(6):345-346. https://doi.org/10.1002/clc.22537
  67. Zhou Y, Ma J, Zhu W. Efficacy and safety of Direct Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation Across BMI Categories: A Systematic Review and Meta-Analysis. Am J Cardiovasc Drugs. 2020;20(1):51-60. https://doi.org/10.1007/s40256-019-00362-4
  68. Rutherford OW, Jonasson C, Ghanima W, Söderdahl F, Halvorsen S. Effectiveness and safety of oral anticoagulants in elderly patients with atrial fibrillation. Heart. 2022;108(5):345-352. https://doi.org/10.1136/heartjnl-2020-318753
  69. Flaker G, Lopes RD, Al-Khatib SM, Hermosillo AG, Hohnloser SH, Tinga B, et al.; ARISTOTLE Committees and Investigators. Efficacy and Safety of Apixaban in Patients After Cardioversion for Atrial Fibrillation: Insights From the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). J Am Coll Cardiol. 2014;63(11):1082-1087. https://doi.org/10.1016/j.jacc.2013.09.062
  70. Rago A, Papa AA, Attena E, Parisi V, Golino P, Nigro G, et al. Direct Current Cardioversion in Atrial Fibrillation Patients on Edoxaban Therapy Versus Vitamin K Antagonists: a Real-world Propensity Score-Matched Study. Cardiovasc Drugs Ther. 2021;35(5):1003-1007. https://doi.org/10.1007/s10557-020-07078-7
  71. Pazan F, Collins R, Gil VM, Hanon O, Hardt R, Hoffmeister M, et al. A Structured Literature Review and International Consensus Validation of FORTA Labels of Oral Anticoagulants for Long-Term Treatment of Atrial Fibrillation in Older Patients (OAC-FORTA 2019). Drugs Aging. 2020;37(7):539-548. https://doi.org/10.1007/s40266-020-00771-0
  72. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, et al.; ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330-1393. https://doi.org/10.1093/eurheartj/ehy136
  73. Faraoni D, Levy JH, Albaladejo P, Samama CM; Groupe d’Intérêt en Hémostase Périopératoire. Updates in the perioperative and emergency management of non- vitamin K antagonist oral anticoagulants. Crit Care. 2015;19(1):203. https://doi.org/10.1186/s13054-015-0930-9
  74. Alghadeer S, Hornsby L. Assessment of novel oral anticoagulant use within a community teaching hospital. Saudi Pharm J. 2017;25(1):93-98. https://doi.org/10.1016/j.jsps.2016.02.002.
  75. Salmonson T, Dogné JM, Janssen H, Garcia Burgos J, Blake P. Non-vitamin-K oral anticoagulants and laboratory testing: now and in the future: Views from a workshop at the European Medicines Agency (EMA). Eur Heart J Cardiovasc Pharmacother. 2017;3(1):42-47. https://doi.org/10.1093/ehjcvp/pvw032
  76. Hicks T, Stewart F, Eisinga A. NOACs versus warfarin for stroke prevention in patients with AF: a systematic review and meta-analysis. Open Heart. 2016 Jan 18;3(1):e000279. https://doi.org/10.1136/openhrt-2015-000279
  77. Pollack CV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, et al. Idarucizumab for Dabigatran Reversal – Full Cohort Analysis. N Engl J Med. 2017;377(5):431-441. https://doi.org/1010.1056/NEJMoa1707278
  78. Harinstein LM, Morgan JW, Russo N. Treatment of Dabigatran-Associated Bleeding: Case Report and Review of the Literature. J Pharm Pract. 2013;26(3):264-269. https://doi.org/10.1177/0897190012465955
  79. Hu TY, Vaidya VR, Asirvatham SJ. Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab. Vasc Health Risk Manag. 2016;12:35-44. https://doi.org/10.2147/VHRM.S89130
  80. Lu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ, Abe K, Lee G, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med. 2013;19(4):446-451. https://doi.org/10.1038/nm.3102
  81. Connolly SJ, Milling TJ Jr, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, et al.; ANNEXA-4 Investigators. Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. N Engl J Med. 2016;375(12):1131-1141. https://doi.org/10.1056/NEJMoa1607887
  82. Moudallel S, Cornu P, Dupont A, Steurbaut S. Determinants for under- and overdosing of direct oral anticoagulants and physicians’ implementation of clinical pharmacists’ recommendations. Br J Clin Pharmacol. 2022;88(2):753-763. https://doi.org/10.1111/bcp.15017
  83. Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther. 2005;78(4):412-421. https://doi.org/10.1016/j.clpt.2005.06.011
  84. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al.; RE-LY Steering Committee and Investigators. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2009;361(12):1139-1151. https://doi.org/10.1056/NEJMoa0905561
  85. Mavrakanas T, Bounameaux H. The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism. Pharmacol Ther. 2011;130(1):46-58. https://doi.org/10.1016/j.pharmthera.2010.12.007
  86. Sarah S. The Pharmacology and Therapeutic Use of Dabigatran Etexilate. J Clin Pharmacol. 2013;53(1):1-13. https://doi.org/10.1177/0091270011432169
  87. Burness CB, McKeage K. Dabigatran Etexilate: A Review of its Use for the Prevention of Venous Thromboembolism after Total Hip or Knee Replacement Surgery. Drugs. 2012;72(7):963-986. https://doi.org/10.2165/11209080-000000000-00000
  88. Levy JH, Ageno W, Chan NC, Crowther M, Verhamme P, Weitz JI; Subcommittee on Control of Anticoagulation. When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost. 2016;14(3):623-627. https://doi.org/10.1111/jth.13227
  89. Farina N, Miller JT. Pharmacologic Reversal of Direct Oral Anticoagulants. Crit Care Nurs Q. 2018;41(2):121-128. https://doi.org/10.1097/CNQ.0000000000000193
  90. Alhousani M, Malik SU, Abu-Hashyeh A, Poznanski NJ, Al-Hasan S, Roth DF, et al. Using oral anticoagulants among chronic kidney disease patients to prevent recurrent venous thromboembolism: A systematic review and meta-analysis. Thromb Res. 2021;198:103-114. https://doi.org/10.1016/j.thromres.2020.11.036
  91. Cline L, Generoso EMG, D’Apice N, Dellinger SK, Tovey A, Clark NP, et al. Effectiveness and safety of direct oral anticoagulants in patients with venous thromboembolism and creatinine clearance < 30 mL/min. J Thromb Thrombolysis. 2023;55(2):355-364. https://doi.org/10.1007/s11239-022-02758-7
  92. Karamichalakis N, Georgopoulos S, Vlachos K, Liatakis I, Efremidis M, Sideris A, et al. Efficacy and safety of novel anticoagulants in the elderly. J Geriatr Cardiol. 2016;13(8):718-723. https://doi.org/10.11909/j.issn.1671-5411.2016.08.011
  93. Prescribing information. Eliquis (apixaban). Princeton, NJ: Bristol-Myers Squibb Company; 2014 [cited 2023 Aug 12]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202155s006lbl.pdf
  94. Diener HC, Aisenberg J, Ansell J, Atar D, Breithardt G, Eikelboom J, et al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. Eur Heart J. 2017;38(12):860-868. https://doi.org/10.1093/eurheartj/ehw069
  95. Van der Linden L, Hias J, Vanassche T. The value and limitations of new oral anticoagulant plasma level assessments. Eur Heart J Suppl. 2022;24(Suppl A):A32-A41. https://doi.org/10.1093/eurheartj/suab153
  96. Fernández CS, Gullón A, Formiga F. The problem of underdosing with direct-acting oral anticoagulants in elderly patients with nonvalvular atrial fibrillation. J Comp Eff Res. 2020;9(7):509-523. https://doi.org/10.2217/cer-2019-0197
  97. Sanghai S, Wong C, Wang Z, Clive P, Tran W, Waring M, et al. Rates of Potentially Inappropriate Dosing of Direct-Acting Oral Anticoagulants and Associations With Geriatric Conditions Among Older Patients With Atrial Fibrillation: The SAGE-AF Study. J Am Heart Assoc. 2020 Mar 17;9(6):e014108. https://doi.org/10.1161/JAHA.119.014108
  98. Barakat AF, Jain S, Masri A, Alkukhun L, Senussi M, Sezer A, et al. Outcomes of Direct Oral Anticoagulants in Atrial Fibrillation Patients Across Different Body Mass Index Categories. JACC Clin Electrophysiol. 2021;7(5):649-658. https://doi.org/10.1016/j.jacep.2021.02.002
  99. Royal College of Obstetricians and Gynecologists. Reducing the risk of venous thromboembolism during pregnancy and the puerperium: Green-top Guideline No 37A. 2015.
  100. Chi G, Yee MK, Kalayci A, Kerneis M, AlKhalfan F, Mehran R, et al. Total bleeding with rivaroxaban versus warfarin in patients with atrial fibrillation receiving antiplatelet therapy after percutaneous coronary intervention. J Thromb Thrombolysis. 2018;46(3):346-350. https://doi.org/10.1007/s11239-018-1703-5
  101. Eikelboom J, Merli G. Bleeding with Direct Oral Anticoagulants vs Warfarin: Clinical Experience. Am J Med. 2016;129(11S):S33-S40. https://doi.org/10.1016/j.amjmed.2016.06.003
Published
2023-09-28
How to Cite
Vozniuk, L. A., Dzekan, O. V., & Siromakha, S. O. (2023). Non-Vitamin K Antagonist Oral Anticoagulants in Differentiated Approach to the Use in Cardiological Practice: Literature Review. Ukrainian Journal of Cardiovascular Surgery, 31(3), 111-126. https://doi.org/10.30702/ujcvs/23.31(03)/VD041-111126
Issue
Ukrainian Journal of Cardiovascular Surgery Vol 31 No 3 2023
Section
GENERAL ISSUES OF TREATMENT OF PATIENTS WITH CARDIOVASCULAR PATHOLOGY

Most read articles by the same author(s)